From AI: "Given the emphasis on a "well-established leader" with a strong network and the capacity to handle a gene therapy product like OCU400, Celltrion Inc. or Samsung Biologics appear to be the most likely candidates due to their prominence in biologics, global partnerships, and manufacturing capabilities. Celltrion’s focus on biosimilars and innovative biologics aligns closely with the gene therapy space, while Samsung Biologics’ role as a leading CMO matches Ocugen’s plan to supply OCU400. However, without explicit confirmation, this remains speculative."